Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

IPA

ImmunoPrecise Antibodies (IPA)

ImmunoPrecise Antibodies Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IPA
DateTimeSourceHeadlineSymbolCompany
29/03/202405:35Business WireInterSystems et BioStrand, filiale d’IPA, collaborent au lancement de l’intégration innovante de la recherche vectorielle et de LENSai dans les applications de soins de santé pilotées par l’IANASDAQ:IPAImmunoPrecise Antibodies Ltd
28/03/202422:02Business WireInterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare ApplicationsNASDAQ:IPAImmunoPrecise Antibodies Ltd
21/03/202404:52Business WireIPA acquiert l'instrument Carterra LSA® pour améliorer la découverte d'anticorps et renforcer ses développements en matière d'IANASDAQ:IPAImmunoPrecise Antibodies Ltd
20/03/202422:02Business WireIPA Acquires the Carterra LSA® Instrument to Enhance Antibody Discovery and Bolster Its AI DevelopmentsNASDAQ:IPAImmunoPrecise Antibodies Ltd
15/03/202410:39Business WireIPA présente ses résultats financiers et les récents points forts de son activité pour le troisième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
14/03/202423:05Business WireIPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
08/03/202407:24Business WireBioStrand, filiale d'IPA, annonce une avancée majeure dans les sciences du vivant avec son Advanced Foundation AI Model utilisant l'empilement LLM et la technologie HYFTNASDAQ:IPAImmunoPrecise Antibodies Ltd
08/03/202403:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
07/03/202423:02Business WireIPA’s subsidiary BioStrand Unveils Major Breakthrough in Life Sciences with Advanced Foundation AI Model Utilizing LLM Stacking and HYFT TechnologyNASDAQ:IPAImmunoPrecise Antibodies Ltd
05/03/202408:50Business WireL'IPA publiera ses résultats financiers et les faits marquants de sa récente activité pour le troisième trimestre de l'exercice 2024, le 14 mars 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
05/03/202400:01Business WireIPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2024 on March 14, 2024NASDAQ:IPAImmunoPrecise Antibodies Ltd
24/02/202409:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
24/02/202409:26Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
16/02/202407:12Edgar (US Regulatory)Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/01/202405:53Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:IPAImmunoPrecise Antibodies Ltd
11/01/202405:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202307:08Business WireIPA présente ses résultats financiers et les récents points forts de son activité pour le deuxième trimestre de l’exercice 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:48Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:38Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
15/12/202300:01Business WireIPA Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2024*NASDAQ:IPAImmunoPrecise Antibodies Ltd
09/12/202313:57Business WireIPA annonce la clôture d'une offre publique d'actions ordinaires pour un montant de 1 265 million de dollarsNASDAQ:IPAImmunoPrecise Antibodies Ltd
09/12/202309:11Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
09/12/202309:00Business WireIPA Announces Closing of $1.265 Million Public Offering of Common SharesNASDAQ:IPAImmunoPrecise Antibodies Ltd
08/12/202308:53Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IPAImmunoPrecise Antibodies Ltd
07/12/202309:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202323:57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202323:00Business WireIPA annonce le prix des actions ordinaires de son émission publique de 1,1 million USDNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202323:00Business WireIPA Announces Pricing of $1.1 Million Public Offering of Common SharesNASDAQ:IPAImmunoPrecise Antibodies Ltd
06/12/202322:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IPAImmunoPrecise Antibodies Ltd
 Showing the most relevant articles for your search:NASDAQ:IPA